Quercetin for fibrotic lung disease
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests whether taking quercetin, a natural supplement, can help people with fibrotic interstitial lung diseases (a group of conditions that cause scarring in the lungs). If you have been diagnosed with idiopathic pulmonary fibrosis (IPF) or another fibrotic ILD and are on standard treatments, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with idiopathic pulmonary fibrosis (IPF) or another fibrotic interstitial lung disease (ILD).
- You are taking one of the standard treatments for lung scarring (nintedanib or pirfenidone) or other approved immunosuppressive therapy.
- You have not been diagnosed with other lung diseases like asthma, as confirmed by a low FeNO test (a breath test that measures inflammation).
- You are able to start taking quercetin within one week of your first study visit.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This study tests whether adding a cough suppressant called dextromethorphan to the standard IPF medication nintedanib helps improve cough and lung function better than nintedanib alone. It is a 12-week treatment phase with a 1-week follow-up, designed for people with moderate IPF.
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
This trial tests an inhaled drug called LTI-03 to see if it can help people with idiopathic pulmonary fibrosis (IPF). It may be an option for those with moderate lung function who are stable on their current treatment.
This trial is testing a new medication called HSK50042 to see if it can help people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. If you have IPF and meet some basic health criteria, you might be able to join.
This study looks at how patients and doctors decide on treatment for pulmonary fibrosis. It aims to understand the impact of side effects from antifibrotic medicines on treatment choices.
Hear when a new Progressive Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.